

2019-441 - FOI request - Cutaneous Squamous Cell Carcinoma

Question 1 - How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?	50 adult patients																
Question 2 - How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?	1 adult patient																
Question 3 - Of these how many are not candidates for Curative surgery or Curative Radiation? *	Patients with metastatic skin cancers melanoma/ SCC are not candidates for curative surgery or radiation																
Question 4 - In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following: <table border="1" data-bbox="193 1160 1126 1644"> <tr> <td data-bbox="193 1160 975 1328">Complex surgery only (e.g. patients with significant comorbidities, large reconstructions or amputations leading to significant loss of function or disfigurement)</td> <td data-bbox="975 1160 1126 1328"></td> </tr> <tr> <td data-bbox="193 1328 975 1395">Surgery + Radiotherapy (adjuvant / neoadjuvant)</td> <td data-bbox="975 1328 1126 1395"></td> </tr> <tr> <td data-bbox="193 1395 975 1429">Radiotherapy</td> <td data-bbox="975 1395 1126 1429"></td> </tr> <tr> <td data-bbox="193 1429 975 1462">Chemotherapy** only</td> <td data-bbox="975 1429 1126 1462"></td> </tr> <tr> <td data-bbox="193 1462 975 1496">Chemotherapy** + Radiotherapy</td> <td data-bbox="975 1462 1126 1496"></td> </tr> <tr> <td data-bbox="193 1496 975 1563">Surgery + Chemotherapy** (adjuvant / neoadjuvant)</td> <td data-bbox="975 1496 1126 1563"></td> </tr> <tr> <td data-bbox="193 1563 975 1597">Other (Please state)</td> <td data-bbox="975 1563 1126 1597"></td> </tr> <tr> <td data-bbox="193 1597 975 1644">Palliative Care / Best Supportive Care</td> <td data-bbox="975 1597 1126 1644"></td> </tr> </table>	Complex surgery only (e.g. patients with significant comorbidities, large reconstructions or amputations leading to significant loss of function or disfigurement)		Surgery + Radiotherapy (adjuvant / neoadjuvant)		Radiotherapy		Chemotherapy** only		Chemotherapy** + Radiotherapy		Surgery + Chemotherapy** (adjuvant / neoadjuvant)		Other (Please state)		Palliative Care / Best Supportive Care		0 adult patients
Complex surgery only (e.g. patients with significant comorbidities, large reconstructions or amputations leading to significant loss of function or disfigurement)																	
Surgery + Radiotherapy (adjuvant / neoadjuvant)																	
Radiotherapy																	
Chemotherapy** only																	
Chemotherapy** + Radiotherapy																	
Surgery + Chemotherapy** (adjuvant / neoadjuvant)																	
Other (Please state)																	
Palliative Care / Best Supportive Care																	
Question 5 - Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)? If yes, please state which?	We are not participating in any clinical trials for any skin cancers at present at the RBH, They are all currently being done at the Christie																

**Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely*

CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection

** Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:*

CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition

Clinical judgement that tumour might not respond to RT

Factors / conditions contradicting for RT

Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does

*** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide*